Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced preliminary unaudited sales ...
Projecting 25.2% year-over-year sales growth, Globus Medical projects Q4 2025 revenue of $823.2 million. Analysts, on the ...
Globus Medical (GMED) is back in focus after its preliminary fourth quarter 2025 revenue of about US$823.2 million topped ...
Investor's Business Daily on MSN
Globus Medical stock operating in a buy zone after strong preliminary results
Medical sector leader Globus Medical is in a buy zone from a cup-with-handle base that has a buy point of 92.48.
Globus Medical, a firm on the Top 100 Medical Device Companies List, had what some analysts are calling a disappointing quarter. The Audubon, PA-based company came up short in the revenue and earnings ...
Globus Medical’s full-year revenue for 2025 is projected to reach nearly $3 billion, according to preliminary financial results. Full-year revenue in 2025 is expected to increase 25.2% year over year ...
Shares of Globus Medical rose after the company issued preliminary fourth-quarter sales numbers and a 2026 outlook that both beat analysts' expectations. The stock gained 10% to $99.74 in after-hours ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback